Drug intelligence / Profile preview

HEC126764

Development stage: Preclinical
Lead developer: Shenzhen Dongyangguang Industry
Modality: Small Molecules
Administration: Oral

Overview

HEC126764 is an investigational drug candidate being developed by Shenzhen Dongyangguang Industry (HEC Pharma) for the treatment of diabetic nephropathy. While specific details regarding its molecular target and mechanism of action are not publicly disclosed in standard pharmacological databases, it is part of HEC Pharma's metabolic and renal disease pipeline. The drug is currently in early-stage clinical development, aimed at addressing the progressive kidney damage associated with diabetes.

Beyond the preview

Go deeper on HEC126764.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HEC126764.

Explore the full profile